CD8+ S100B+ T cells

Overview

CD8+ S100B+ T cells represent a specialized subset of cytotoxic T lymphocytes characterized by the expression of the S100B protein, which is implicated in various immune responses and tumor microenvironments. These T cells play a crucial role in the adaptive immune system, particularly in recognizing and eliminating cancer cells. The presence of S100B in CD8+ T cells may influence their activation, proliferation, and cytotoxic functions, making them a significant focus in cancer immunotherapy research. Understanding the mechanisms governing CD8+ S100B+ T cell activity can provide insights into enhancing anti-tumor immunity and developing novel therapeutic strategies.

Focus of Latest Publications

Recent studies have highlighted the importance of CD8+ S100B+ T cells in various cancer contexts, particularly in relation to tumor immunogenicity and the tumor microenvironment. For instance, a study published in Oncoimmunology (PMID: 42057381) demonstrated that BET inhibition using JQ1 enhanced the proliferation of tumor-infiltrating lymphocytes (TILs), leading to an enriched population of CD8+ T cells, suggesting a pivotal role for these cells in anti-tumor responses. Another study in Epigenetics (PMID: 42118848) reported that a high-risk group exhibited an immunosuppressive microenvironment with reduced CD8+ T cells, indicating the prognostic impact of cytotoxic T-cell infiltration on tumor progression.

Moreover, research in Blood Advances (PMID: 41941698) emphasized the significance of CD8+ T cell subsets in driving immune responses post-vaccination, while a study in Cancer Cell (PMID: 42242231) associated reduced intratumoral regulatory T cells with enhanced CD8+ T cell effector function, underscoring the dynamic interplay between different immune cell types in the tumor microenvironment. Combination therapy with anti-PD-1 antibodies enhanced CD8+ T-cell recruitment and function in hepatocellular carcinoma models (PMID: 42111772), further illustrating the relevance of cytotoxic T cells in immunotherapy and resistance reversal.

Additionally, the role of CD8+ S100B+ T cells in modulating immune responses was explored in the context of various therapeutic strategies, including the use of lipid nanoparticles (PMID: 42057038) and adoptive T cell transfer (PMID: 41998001). These studies collectively suggest that enhancing the function and infiltration of CD8+ S100B+ T cells could be a promising approach for improving cancer immunotherapy outcomes.

Key Publications

NEWJun DGAT1 Inhibition Induces Ferroptosis and Enhances Cancer Immunotherapy Efficacy. (Cancer research, 2026, PMID 41812065): "...enhanced ICB therapy efficacy by promoting increased infiltration of cytotoxic T lymphocytes."
Jun Design, synthesis, and in vitro/in vivo biological evaluation of Artesunate-Ebselen derivatives: GPX4-targeted ferroptosis induction and synergistic antitumor immune activation in colorectal cancer. (Bioorganic chemistry, 2026, PMID 41855635): "Flow cytometry analysis of immune cells in tumor-bearing mice showed that compound 5k significantly increased the proportion of CD4+ T cells in the spleen (6.2% vs. 3.5% in the control group) and promoted the infiltration of CD8+ cytotoxic T cells into tumor tissues (7.2% vs. 0.9% in the control group), indicating activation of the antitumor immune response."
Jun Discriminating Post-Transplant Rejection from Infection by Detecting TCR-CD3 Oligomerization on Extracellular Vesicles Using a Ratiometric Caliper Probe. (Journal of the American Chemical Society, 2026, PMID 42204898): "to quantify the ratio of TCR-CD3 oligomeric to monomeric EVs derived from CD8+ cytotoxic T cells."
Jun Baiting-enhanced extravasation of lipid nanoparticles for targeted co-delivery of decitabine and siTNF-α to the bone marrow niche in leukemia therapy. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41905408): "...leading to enhanced CD8+ T, natural killer (NK), and natural killer T (NKT) cell infiltration in the bone marrow site."
Jun Toward Nano-Nutritional Medicine: A Remotely Activated Trans-Vaccenic Acid-Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy. (Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026, PMID 42261893): "...the released TVA not only reduces CD8+ T cell exhaustion by activating cAMP-PKA-CREB axis..."
Jun Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42234523): "...in association with reduced intratumoral regulatory T cells and reinforcement of CD8+ T cell effector function."
Jun Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy. (Blood advances, 2026, PMID 41941698): "Responses were primarily driven by CD4+ central memory and cytotoxic CD8+ T-cell subsets."
Jun Pathogenesis of diffuse large B cell lymphoma proteogenotypes. (Cancer cell, 2026, PMID 42242231): "The PG4 tumor microenvironment is characterized by exhausted CD8+ T cells."
Jun Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL. (Blood, 2026, PMID 41746860): "High responders to glofitamab possessed CD8+ T cells with consistently higher cytotoxic and activation signatures across effector differentiation states, whereas low responders showed enrichment of exhausted CD8+ T cells with enhanced expression of exhaustion markers (T-cell immunoglobulin and ITIM domain [TIGIT], LAG3, and PD1)."
Jun Injectable Binary-Amplified Cascade Hydrogels Suppress Post-Incomplete Microwave Ablation Relapse via Integrated Metallo-Metabolic-Immunomodulation. (ACS nano, 2026, PMID 42150126): "Crucially, S/CuCo@HD synergizes with anti-PD-1 therapy to reinvigorate cytotoxic T lymphocytes and establish durable immune memory, effectively suppressing tumor relapse and metastasis post-iMWA, offering an integrated metallo-metabolic-immunomodulation strategy with promising translational potential for comprehensive HCC management."

Show 56 more publications

Jun The role of cellular senescence in immune-metabolic features and prognosis of ovarian cancer: an integrated analysis based on single-cell sequencing and multi-omics data. (GeroScience, 2026, PMID 42228240): "The high-risk group was associated with greater TMB, platinum resistance-related features, increased immune and stromal scores, reduced tumor purity, a lower proportion of CD8+ T cells, and higher expression of regulatory T cells, macrophages, and immune checkpoints, suggesting a link with an immunosuppressive tumor microenvironment."
Jun Asiatic acid promotes CD8+ T cell-mediated antitumor immunity by targeting HDAC8/CXCL10 axis in hepatocellular carcinoma. (Acta pharmacologica Sinica, 2026, PMID 41644738): "We showed that AA treatment effectively converted "cold tumors" into "hot tumors" by promoting CD8+ T cell infiltration and activation in HCC."
Jun Cancer cell membrane and iRGD peptide co-modified cantharidin liposomes for targeted therapy and immunotherapy of triple-negative breast cancer. (Free radical biology & medicine, 2026, PMID 41812835): "DAMPs activated anti-tumor immunity by promoting the maturation of dendritic cells (DCs) and the proliferation of cytotoxic T lymphocytes (CD8+ T cells)."
Jun Antiangiogenic DPPA-nanoparticles combined with an immune checkpoint inhibitor for the treatment of unresectable hepatocellular carcinoma. (Materials today. Bio, 2026, PMID 42111772): "In both subcutaneous and orthotopic allograft models, the combination of LNDPPA and an anti-PD-1 antibody enhanced CD8+ T cells recruitment and function and exhibited superior tumor growth inhibition compared to the conventional sorafenib plus an anti-PD-1 antibody."
Jun Prediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens. (Cancer cytopathology, 2026, PMID 42137987): "Tumor-infiltrating lymphocytes are prognostic and predictive biomarkers of breast cancer; however, conventional assessment is hindered by invasiveness and subjective evaluation, limiting clinical reproducibility."
Jun LILRB2+ monocytes reshape the immune activation landscape in immunotherapy with non-small cell lung cancer: Evidence from real-world cohorts and single-cell analyses. (International journal of biological macromolecules, 2026, PMID 42069195): "LILRB2+ monocytes promoted the activation of CD8+ T cells, further enhanced the anti-tumor efficacy of PD-1 blockade."
May The effect of moderate physical activity on NK cells populations and cytotoxic T lymphocytes in young, healthy women. (PloS one, 2026, PMID 42213729): "Physical exercise activates innate and adaptive immunity, boosting the circulation and function of NK cells and cytotoxic T lymphocytes, key players in cancer surveillance."
May Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides. (Signal transduction and targeted therapy, 2026, PMID 42204141): "In vivo studies have demonstrated enhanced CD8⁺ T-cell tumor infiltration and activation, notably when combined with immune checkpoint blockade or adoptive T-cell transfer."
May Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer. (Science translational medicine, 2026, PMID 42202048): "These myCAFs reciprocally expanded eTreg cells and exhausted CD8+ T cells, thereby converting genomic instability-driven immune activation into suppression and limiting poly(ADP-ribose) polymerase inhibitor (PARPi) efficacy."
May Restorative effect of Rehmanniae radix praeparata on T-cell and NK-cell-mediated immune reconstitution in mice following radiation-induced injury. (Journal of radiation research, 2026, PMID 42014349): "CD3+, CD4+, CD8+ T and NK cells decreased significantly on Days 4 to 6 and largely recovered by Days 9 to 11 post-IR."
May GSK-3 regulates CD4-CD8 cooperation for super-armed CD8+ cytolytic T cells in immunotherapy against tumors. (Signal transduction and targeted therapy, 2026, PMID 42156357): "GSK-3 inhibition and reduced expression synergized with PD-1 blockade to 'super-arm' cytolytic CD8⁺ T cells, characterized by upregulation of perforin and seven distinct granzymes."
May Meloxicam-1-d-MT Dual-Drug Hydrogel Serves as an Immunomodulator to Reverse Tumor Postoperative Recurrence and Metastasis. (ACS applied materials & interfaces, 2026, PMID 42081317): "Importantly, the Ge1MT/Mel hydrogel markedly stimulates a potent antitumor immune response in the cancer lesion microenvironment, increasing antitumor immune cells including CD8+ T cells, as well as elevating antitumor cytokines such as interferon-γ."
May Validation of DoriVac (DNA Origami Vaccine) Efficacy in a Metastatic Melanoma Model. (ACS applied materials & interfaces, 2026, PMID 42052817): "Our results also indicate an increased activation of antigen-presenting cells, NK cells, CD4+ T cells, and CD8+ T cells in comparison to the control groups."
May Polymannose-Guided Repolarization of Tumor-Associated Macrophages for Enhanced Photodynamic Immunotherapy. (ACS macro letters, 2026, PMID 42050361): "In vivo experiments demonstrated that FI@PMD increased the infiltration of CD8+ cytotoxic T cells in tumor tissues to 2.85-fold of that in the PBS group while reducing the proportion of Treg cells to 0.86-fold."
May Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC. (The Journal of clinical investigation, 2026, PMID 41805727): "Among various types of intratumoral lymphocytes, including Th1, Treg, and NK cells, only CD8+ T cells (tumor-infiltrating lymphocytes [TILs]) were associated with ICI efficacy."
May In vivo CRISPR screens identify CBX4 as an epigenetic regulator for cancer immunotherapy. (The Journal of clinical investigation, 2026, PMID 41915438): "Deficiency of CBX4 in macrophages or tumor cells induced robust antitumor immunity and increased infiltration and the cytotoxic activity of CD8+ T cells and NK cells, thereby heightening the sensitivity of ICB treatment."
Dec Identification of pyroptosis-related hub genes and immune cell infiltration in IgA nephropathy via bioinformatics analysis. (Renal failure, 2026, PMID 42135973): "Immune cell infiltration analysis showed higher levels of CD8+ T cells, macrophages, and neutrophils in IgAN."
May Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation. (Blood, 2026, PMID 41587074): "...leading to significantly reduced activation and proliferation of CD4+ and CD8+ T cells."
May Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models. (Nature biotechnology, 2026, PMID 42129506): "These IR-mRNAs activate APCs in tumors, significantly increasing activated type 1 conventional dendritic cells, immunostimulatory cytokines and priming antitumor CD8+ T cells."
May Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy. (Developmental cell, 2026, PMID 41895257): "Quiescent PTCs possess aggressive stem-like traits and orchestrate an immunosuppressive microenvironment characterized by CD96+CD8+ T cell infiltration in an orthotopic CRC mouse model."
May Targeted introduction of T cell receptor genes at the TRAC locus in cytotoxic T lymphocytes regenerated from human iPSCs by genome editing. (Biochemical and biophysical research communications, 2026, PMID 41856057): "Cytotoxic T lymphocytes (CTLs) regenerated from induced pluripotent stem cells (iPSCs) have emerged as an ideal cellular material for introduction of T-cell receptor (TCR) genes specific for defined tumor antigens, as they can be expanded virtually indefinitely while retaining potent cytolytic activity."
May Glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies enhances immunotherapy for melanoma brain metastases. (Science advances, 2026, PMID 42127192): "Ultimately, this combination promoted CD8+ T cell activation and residency, pro-inflammatory macrophage polarization, and reduced Treg cell infiltration, thereby eliciting a strong antitumor effect."
May Metabolic dysfunction-associated steatohepatitis exacerbated by Clostridium perfringens-derived ammonia is attenuated by tripeptide DT-109. (The Journal of clinical investigation, 2026, PMID 42118590): "Elevated ammonia levels triggered FosB-mediated upregulation of chemokine C-C motif ligand 5 (CCL5) in CD8+ T cells, which in turn drove T cell cytotoxicity in the liver."
May Acetylcholinesterase inhibitor therapy mitigates hypertension in lupus mice. (Clinical science (London, England : 1979), 2026, PMID 42003680): "Galantamine treatment also reduced splenic CD19+ B cells and kidney CD8+ T cells in SLE mice."
May A relative methylation ordering biomarker of lactylation-related genes predicts prognosis and therapeutic response in cutaneous melanoma. (Epigenetics, 2026, PMID 42118848): "The high-risk group exhibited an immunosuppressive microenvironment with reduced CD8+ T cells and B cells and increased monocytes (p<0.05, Wilcoxon test)."
May Multi-omics profiling reveals tumor microenvironment characteristics linked to immunotherapy response and prognosis in non-small cell lung cancer. (NPJ precision oncology, 2026, PMID 42115771): "We identified elevated infiltration of ZNF683 + CD8 + T cells as a crucial subset enriched in responders, with ZNF683 expression serving as a robust indicator of immunotherapy responsiveness."
May Fabrication of Electrospun PCL/PEO Microfibers with Fe3O4 Nanoparticles for Magnetic Hyperthermia: Immunocompatibility Assessment Using CD14+ Monocytes, CD4+ and CD8+ T Cells, and CD56+ NK Cells In Vitro. (ACS biomaterials science & engineering, 2026, PMID 41984521): "The biocompatibility and immunocompatibility of PCL/PEO/Fe3O4 MFs were then tested using four types of human immune cells, namely, CD14+ monocytes, CD4+ helper, CD8+ cytotoxic T cells, and CD56+ NK cells."
May Photothermally Triggered Bacterial-Manganese Immune Amplifier Enables Spatiotemporal STING Hyper-Activation against Cold Tumors. (Nano letters, 2026, PMID 42029112): "recruits CD8+ T cells to drive systemic antitumor immunity"
May Chirality-Driven Immune Checkpoint Modulation by Chiral Iridium(III) Nanoparticles. (Journal of the American Chemical Society, 2026, PMID 42018475): "...and the recruitment of effector CD8+ T cells to remodel the tumor microenvironment."
May Lipid droplet-regulated multipathway-induced type I interferon tempest for ferroptosis-immune synergistic therapy of tumors. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41692047): "the accumulated lipid droplets are associated with the inhibition of the maturation of dendritic cells and then the expression of CD8+ T cells without affecting the expression of memory T cells."
May Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study. (Signal transduction and targeted therapy, 2026, PMID 42071008): "Analysis of blood and tissue samples from patients with different treatment outcomes revealed significant activation of CD8+ T cells, NK cells, and M1 macrophage subsets in the tumor microenvironment of patients achieving pCR."
May In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs. (Science immunology, 2026, PMID 42102231): "Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA-LNPs for rapid, efficient, and transient in vivo modification of Teff cells."
May Targeted enhancement of antigen cross-presentation capability of M2-like tumor-associated macrophages to boost glioblastoma immunotherapy. (Biomaterials, 2026, PMID 41370882): "Macrophage antigen cross-presentation plays a vital role in activating CD8+ T cells for tumor immunotherapy."
May Rosmarinic acid/Se4+ self-assembled nanoparticles for combinational therapy of triple-negative breast cancer. (Biomaterials advances, 2026, PMID 41512467): "Consequently, in a syngeneic TNBC mouse model, RA-Se@M significantly suppressed tumor growth and, when combined with anti-PD-1 therapy, promoted profound intratumoral infiltration of cytotoxic T cells and achieved the most potent therapeutic outcome."
May Selenium nanoparticles as adjunctive therapy in sepsis: A pilot randomized clinical trial. (Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2026, PMID 41825095): "SeNPs supplementation was associated with improved immune function, reflected by higher total lymphocyte counts and increased absolute counts of CD3+, CD4+, and CD8+ T cell subsets on days 4, 7, and 10."
May The iterative shrinkage thresholding algorithm reveals dynamic aging trajectories of human T lymphocytes via multidimensional spectral flow cytometry analysis. (International immunopharmacology, 2026, PMID 41833104): "Among all subsets, CD8+ T cells exhibited the greatest sensitivity to age-associated immunophenotypic remodeling, characterized by reduced expression of CD27 and CD28, and increased expression of senescence-associated surface markers including CD57 and KLRG1, together with elevated cytotoxic effector molecules including IFN-γ and granzyme B."
May Spatiotemporal Transcriptomics Characterizes Immune Microenvironment During Mouse Liver Aging. (Aging cell, 2026, PMID 42010880): "marked by enrichment of exhausted CD8+ T cells in aged livers."
May TIMP1 and PKM drive immunosuppression and metabolic remodeling to promote colorectal cancer progression through integrated multi-omics analysis. (International journal of biological macromolecules, 2026, PMID 41966374): "Single-cell RNA sequencing and T cell killing assay confirmed that TIMP1 significantly impaired the tumor-killing capacity and IFN-γ secretion of CD8+ T cells."
May Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer. (The Journal of clinical investigation, 2026, PMID 42065248): "Conventional type-1 dendritic cells (cDC1) are the main mediators of crosspresentation of tumor antigens to CD8+ T cells and provide a context of costimulatory molecules and cytokines that lead to cytotoxic T lymphocyte (CTL) responses."
May Sericin-chitosan nanoassembly-based scalable and biocompatible manganese nanoadjuvant for high-performance inactivated pseudorabies virus vaccine. (International journal of biological macromolecules, 2026, PMID 41941907): "Flow cytometric analysis demonstrated that the nanoadjuvant efficiently promoted maturation of dendritic cells, stimulated the increase of CD4+/CD8+ T cell populations and their activation, and enhanced generation of memory CD4+/CD8+ T cells."
May Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells. (Cancer research communications, 2026, PMID 41960903): "Together, these findings demonstrate that Vidu treatment expands the number of intratumoral and circulating tumor-specific CD8+ T cells and that the number of tumor-specific CD8+ T cells and the antitumor response is sustained by the addition of αPD-1."
May Biomimetic PD-1 macrophage nanoplatform for Cip2a silencing and immune activation in oral squamous cell carcinoma. (Journal of nanobiotechnology, 2026, PMID 42057038): "Importantly, PD-1-functionalized membrane camouflage promotes dendritic cells maturation, increases intratumoral infiltration of CD4+ and CD8+ T cells, and restores antitumor immune responses."
Dec Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8+ T cells. (Oncoimmunology, 2026, PMID 42057381): "Preliminary results using JQ1-treated melanoma cells in a mixed lymphocyte-tumor cell culture (MLTC) markedly enhanced TIL proliferation and resulted in a T cell product enriched for CD8+ T cells."
Apr Biodegradable Nickel Phosphide Mediated Adenosine Metabolism and Hippo Pathway Inhibition for Synergistic Photothermal Immunotherapy. (ACS applied materials & interfaces, 2026, PMID 42003791): "The photothermal performance of NPRA NPs can first promote the recruitment of cytotoxic T lymphocytes (CTLs)."
Apr CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42012954): "to expand CD8+ T cells with Tscm-like features."
Apr Protein kinase Cι-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer. (Cancer letters, 2026, PMID 41720451): "PKCζ-dependent resistance to αPD1 is characterized by increased tumor-associated macrophages (TAMs) infiltration and reduced CD8+T cell numbers."
Apr Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. (Signal transduction and targeted therapy, 2026, PMID 42045172): "This efferocytosis promoted MHC-I degradation via the macrophage lysosomal pathway, leading to CD8+ T cell exhaustion."
Apr Glycan Chemical Structures Dictate Organ- and Cell-Specific Tropism and Immunomodulation of Lipid Nanoparticles. (ACS nano, 2026, PMID 41989838): "Functionally, they elicit potent activation of both CD8+ and CD4+ T cells, the latter being a critical yet rarely achieved response in standard LNP formulations."
Apr Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma. (Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026, PMID 42028639): "Real-time monitoring of kidney-infiltrating cytotoxic T lymphocytes (CTLs) is crucial for evaluating immunotherapy in renal cell carcinoma (RCC)."
Apr CRISPR-based metabolic screening identifies PLCE1 as a pivotal regulator of oncolytic viral antitumor immunity via tumor immune microenvironment remodeling. (Biochemical and biophysical research communications, 2026, PMID 41759376): "The combination therapy has been shown to remodel the tumor immune microenvironment, leading to an increase in CD45+ immune cells and CD8+ T cells, including naïve subsets, and a decrease in FOXP3+ Treg cells."
Apr Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. (Science advances, 2026, PMID 42018612): "We identify CD11c+KLRG1+ effector CD8 T cells (CD11c+TE) as the primary source of IFN-γ, recirculating between blood and secondary lymphoid organs (SLOs), where they undergo apoptosis during contraction."
Apr KSR2 functions as a metabolic checkpoint for anti-PD-1 resistance by reprogramming glucose metabolism. (Cancer immunology, immunotherapy : CII, 2026, PMID 42012646): "This metabolic reprogramming was subsequently associated with an immunosuppressive tumor microenvironment, characterized by reduced infiltration and impaired function of CD8+ T cells, alongside an enrichment of regulatory T cells."
Apr Inhalable Cryo-Shocked Tumor Cells for Synergistic Chemoimmunotherapy. (ACS applied materials & interfaces, 2026, PMID 41947504): "...robust DC activation, M1 macrophage polarization, and significant recruitment of NK cells and CD8+ T cells into the tumor microenvironment."
Apr BANF1 as a potential prognostic biomarker associated with tumor-intrinsic programs and a complex immune landscape in lung adenocarcinoma. (Discover oncology, 2026, PMID 42000935): "CIBERSORT analysis demonstrated enrichment of CD8+ T cells, M1 macrophages, follicular helper T cells, and regulatory T cells, together with selective upregulation of immune checkpoint genes."
Apr NKG2A inhibition promotes NK cell-CD8+ T cell interactions to improve anticancer immunity in ovarian carcinoma. (Nature communications, 2026, PMID 41998001): "crosstalk between NK cells and CD8+ T cells critical for effective antitumor immunity."
Apr Cell-type-specific causal effects of CEBPD in CD8 + S100B + Tcells and ZFP36 in monocytes modulate the protective and risk phenotypes in psoriasis. (Mammalian genome : official journal of the International Mammalian Genome Society, 2026, PMID 41991682): "MR analysis demonstrated that higher CEBPD expression in CD8+ S100B+ T cells was protective (odds ratio [OR]=0.795, P=0.015) for psoriasis."